NLRP3
NLRP3 (NLR Family Pyrin Domain Containing 3) is a cytosolic pattern-recognition receptor that functions as the sensor component of the NLRP3 inflammasome, enabling innate immune cells to detect microbial motifs, endogenous danger signals, and environmental irritants[1]. Upon activation, NLRP3 oligomerizes and recruits the adaptor ASC and pro-caspase-1, leading to inflammasome assembly, caspase-1 activation, and subsequent maturation of the pro-inflammatory cytokines IL-1β and IL-18 as well as gasdermin D-mediated pyroptosis[1][2]. Mechanistically, canonical NLRP3 activation requires a priming step that enhances NLRP3 and pro-inflammatory cytokine expression, followed by an activation step triggered by diverse stimuli including extracellular ATP, microbial toxins, silica particles, and monosodium urate crystals[2]. Through these signaling processes, NLRP3 regulates inflammation, host defense, and immune homeostasis, while excessive activation promotes pathological inflammatory responses[1][3]. Dysregulated NLRP3 inflammasome activity has been implicated in autoinflammatory syndromes, gout, cardiovascular disease, neurodegenerative disorders, inflammatory bowel disease, and other inflammation-associated conditions[1][3][4]. Compared with other inflammasome-forming NOD-like receptors such as NLRP1 and NLRC4, NLRP3 is distinguished by its ability to respond to an exceptionally broad spectrum of pathogen-associated and danger-associated signals rather than a limited set of ligands[1][4]. For experimental applications, selective NLRP3 inhibitors such as MCC950 suppress inflammasome assembly by targeting the NACHT domain and are widely used to investigate NLRP3-dependent inflammatory mechanisms in preclinical disease models[4].
References:
- [1]. Swanson KV, et al. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019 Aug;19(8):477-489. [Content Brief]
- [2]. Shin HJ, et al. Molecular mechanisms of NLRP3 inflammasome activation. Exp Mol Med. 2026 Mar;58(3):650-663. [Content Brief]
- [3]. Chen Y, et al. The NLRP3 inflammasome: contributions to inflammation-related diseases. Cell Mol Biol Lett. 2023 Jun 27;28(1):51. [Content Brief]
-
NLRP3 Related Products (231)
Related Products (231)
-
Recombinant Proteins (1)
-
Antibodies (1)
-
MNP2
0 ImagesCat. No.: HY-P11581MNP2 is a NLRP3-ASC interaction inhibitor. MNP2 selectively binds to the PYD domain of ASC (Ka=149 nM) and blocks ASC-PYM binding (Ka=58 nM), thereby inhibiting the interaction between ASC and NLRP3 and suppressing the formation of the NLRP3 inflammasome. MNP2 inhibits IL-1β release and caspase-1 maturation, and reduces the efflux of potassium and chloride ions. MNP2 prevents mitochondrial damage and reactive oxygen species production, and significantly decreases NLRP3 inflammasome formation in neurodegenerative pathologies induced by β-amyloid, Tau protein and α-synuclein. MNP2 is applicable for the research of neurodegenerative diseases.
-
Clasornoflast
0 ImagesCat. No.: HY-182803CAS No.: 2878442-24-9Synonyms: NLRP3-IN-90Clasornoflast (NLRP3-IN-90) (Compound 1) is a NLRP3 inflammasome inhibitor. Clasornoflast is applicable for inflammation research.
-
NLRP3-IN-8
0 ImagesCat. No.: HY-146594CAS No.: 2768650-56-0
-
NLRP3-IN-15
0 ImagesCat. No.: HY-149122CAS No.: 2767369-71-9NLRP3-IN-15 is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-15 inhibits IL-1β release with an IC50 of 0.114 μM. NLRP3-IN-15 can be used for the research of inflammation.
-
NLRP3-IN-84
0 ImagesCat. No.: HY-178953NLRP3-IN-84 (Compound 32) is a NLRP3 inflammasome inhibitor. NLRP3-IN-84 can interfere with the oligomerization process of NLRP3 by inhibiting the activity of NLRP3 ATPase (IC50 = 158.4 nM). NLRP3-IN-84 inhibits Caspase-1 (IC50 = 27.7 nM), IL-1β release (PBMC: IC50 = 19.5 nM; mPBMC: IC50 = 24.2 nM), and ASC plaque formation (IC50 = 131 nM). NLRP3-IN-84 has no inhibitory activity on NLRC4 and AIM2 inflammasomes. NLRP3-IN-84 exhibits significant in vivo anti-inflammatory effects in a mouse acute peritonitis model. NLRP3-IN-84 can be used for the study of NLRP3-related inflammatory diseases.
-
NLRP3/AIM2-IN-1
0 ImagesCat. No.: HY-144220CAS No.: 3033386-91-0NLRP3/AIM2-IN-1 is an NLRP3/AIM2 inhibitor with an IC50 of 3.136 μM against NLRP3-dependent pyroptosis. NLRP3/AIM2-IN-1 inhibits IL-1β secretion triggered by NLRP3 inflammasome activation. NLRP3/AIM2-IN-1 exhibits moderate anti-pyroptotic activity. NLRP3/AIM2-IN-1 does not inhibit NLRC4 inflammasome activation. NLRP3/AIM2-IN-1 can be used for studying inflammasome-mediated inflammatory diseases.
-
Z1456467176
0 ImagesCat. No.: HY-184711CAS No.: 1606572-10-4Z1456467176 is an allosteric inhibitor of P2X7R. Z1456467176 binds to P2X7R, prevents ATP-induced channel opening and receptor activation, and blocks ATP-induced activation of the NLRP3-caspase-1-IL-1β pathway. Z1456467176 inhibits ATP-induced P2X7R pore formation in macrophages, as well as IL-1β secretion induced by ATP or BzATP. Z1456467176 alleviates gouty joint inflammation in rats. Z1456467176 can be used for the research of gouty arthritis.
-
NEK7 degrader-2
0 ImagesCat. No.: HY-177559CAS No.: 3037413-54-7NEK7 degrader-2 is a NEK7 molecular glue degrader that promotes the formation of the NEK7-compound-CRBN/DDB1 ternary complex. NEK7 degrader-2 reduces the release of IL-1β after NLRP3 inflammasome activation induced by LPS (HY-D1056). NEK7 degrader-2 can be applied in studies related to NEK7-dependent NLRP3 inflammasome activation and inflammatory responses.
-
TN-783
0 ImagesCat. No.: HY-179131TN-783 is an orally active, brain-penetrant NLRP3 (IC50 = 19.3 nM) inhibitor. TN-783 enhances the effects of the GLP-1 receptor agonist semaglutide. TN-783 requires sustained targeted action, not permanent metabolic remodeling. TN-783 can be used for the study of obesity.
-
NLRP3-IN-81
0 ImagesCat. No.: HY-174312CAS No.: 2922814-85-3NLRP3-IN-81 (N102) is a BBB-penetrable inhibitor against NLRP3 inflammasome-dependent pyroptosis with an EC50 of 0.029 μM against cell pyroptosis induced by Nigericin (HY-127019). NLRP3-IN-81 potently inhibits NLRP3-dependent activation of caspase-1 and the release of IL-1β. NLRP3-IN-81 disturbs the interaction of NLRP3 with the adaptor protein ASC and inhibits ASC oligomerization. NLRP3-IN-81 can be used for pyroptosis-related diseases research, such as inflammatory bowel diseases and type 2 diabetes.
-
NLRP3-IN-87
0 ImagesCat. No.: HY-181488CAS No.: 3097745-69-9NLRP3-IN-87 is a selective and orally active NLRP3 inhibitor with a Kd of 0.23 μM. NLRP3-IN-87 binds directly to the NLRP3 NACHT domain, disrupts NLRP3-NEK7 and NLRP3-ASC interactions, inhibits ASC oligomerization, and blocks inflammasome assembly. NLRP3-IN-87 suppresses caspase-1 activation and IL-1β secretion. NLRP3-IN-87 exhibits anti-inflammatory and analgesic activity, reducing joint swelling, inflammation, and pain in an MSU (HY-B2130A)-induced acute gout mouse model. NLRP3-IN-87 can be used for the research of gout.
-
NLRP3-IN-77
0 ImagesCat. No.: HY-171589CAS No.: 2924547-57-7NLRP3-IN-77 (Compound 7n) is a potent NLRP3 inflammasome inhibitor. NLRP3-IN-77 inhibits the viability of THP-1 cells with an IC50 value of 5.36 nM. NLRP3-IN-77 can effectively reduce the secretion of interleukin-1β (IL-1β) and interleukin-18 (IL-18). NLRP3-IN-77 is promising for research of diseases related to the abnormal activation of the NLRP3 inflammasome, such as cancer and inflammatory diseases.
-
Anti-inflammatory agent 114
0 ImagesCat. No.: HY-182778Anti-inflammatory agent 114 is an anti-inflammatory agent. Anti-inflammatory agent 114 binds to the allosteric inhibitory pocket in the NLRP3 NACHT domain. Anti-inflammatory agent 114 inhibits the expression of iNOS, COX-2 and NLRP3. Anti-inflammatory agent 114 can be used for the research of inflammatory diseases.
-
Selnoflast monopotassium
0 ImagesCat. No.: HY-132831CCAS No.: 2260969-37-5Synonyms: Somalix monopotassium; RO-7486967 monopotassium; IZD334 monopotassiumSelnoflast (RO7486967) monopotassium, formerly somalix/RG6418/IZD334 monopotassium, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast monopotassium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast monopotassium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease.
-
MR2938
0 ImagesCat. No.: HY-149087CAS No.: 1044870-65-6
-
CAII-IN-11
0 ImagesCat. No.: HY-180916CAII-IN-11 (Compound A1) is a dual-target compound that contains a hCA II inhibitor (IC₅₀ = 2 nM) portion and a NO donor portion. CAII-IN-11 also has inhibitory activity against hCA IX, hCA XII, and hCA I, with IC50 values of 6, 3, and 152 nM respectively. CAII-IN-11 significantly increases the intracellular cGMP level in human trabecular meshwork cells. CAII-IN-11 reduces the apoptosis of retinal ganglion cells by reducing oxidative stress (ROS levels), inhibiting astrocytes and the NLRP3 inflammasome activation. CAII-IN-11 has hypotensive activity in rabbit models and can be used for the study of glaucoma.
-
NLRP3-IN-88
0 ImagesCat. No.: HY-182102CAS No.: 2557349-73-0NLRP3-IN-88 (Compound 1) is an NLRP3 inhibitor. NLRP3-IN-88 inhibits IL-1β. NLRP3-IN-88 can be used in research on intestinal diseases and inflammatory diseases.
-
NLRP3-IN-38
0 ImagesCat. No.: HY-163497CAS No.: 3033054-46-2NLRP3-IN-38 (Compound 18) is an inhibitor for NOD-like receptor protein 3 (NLRP3), that inhibits NLRP3 inflammasome activation with an EC50 of 23 nM.
